Samuel Oluwadare Olalekan

Mr. Samuel Oluwadare Olalekan

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2024 in The Egyptian Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
SOSamuel Oluwadare Olalekan
Samuel Oluwadare Olalekan
OBOlalekan Olanrewaju Bakare
Olalekan Olanrewaju Bakare
IOIfabunmi Oduyemi Osonuga
Ifabunmi Oduyemi Osonuga
AFAbayomi Samson Faponle
Abayomi Samson Faponle
BABukunola Oluyemisi Adegbesan
Bukunola Oluyemisi Adegbesan
EEEsther Nkechi Ezima
Esther Nkechi Ezima
Background: The gut microbiota (GM) and their metabolites have garnered significant attention for their roles in metabolic syndrome (MetS) and associated conditions. MetS, characterized by a cluster of metabolic abnormalities, significantly increases the risk of cardiovascular disease (CVD), obesity, insulin resistance, and type 2 diabetes mellitus (T2DM). The dysbiosis of gut microbiota, marked by changes in microbial composition and function, has been implicated in the pathogenesis of MetS. Main body: This review synthesizes recent findings elucidating the influence of GM composition and microbiota-derived metabolites on MetS pathogenesis and progression. Notably, alterations in GM composition and dysregulation of metabolites such as short-chain fatty acids (SCFAs), trimethylamine N-oxide (TMAO), polyamines, amino acids, and indole derivatives have been implicated in MetS development. These metabolites play crucial roles in metabolic processes, and their imbalance can trigger or exacerbate metabolic disturbances associated with MetS. Various therapeutic approaches, including dietary interventions, probiotics, prebiotics, and precision medicine targeting specific metabolites, offer promising strategies for managing MetS. These interventions aim to restore a healthy GM balance and regulate the production of beneficial metabolites. Conclusion: The complexity of GM interactions and their systemic effects necessitate more standardized research methodologies. Future investigations focusing on personalized therapeutic interventions and non-invasive diagnostic tools are warranted to address the complexities of MetS management. Advancing our understanding of the GM-metabolite-MetS axis will be crucial for developing effective, targeted treatments and improving patient outcomes in MetS.

21 November 2024 in The Egyptian Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
SOSamuel Oluwadare Olalekan
Samuel Oluwadare Olalekan
OBOlalekan Olanrewaju Bakare
Olalekan Olanrewaju Bakare
POPatrick Godwin Okwute
Patrick Godwin Okwute
IOIfabunmi Oduyemi Osonuga
Ifabunmi Oduyemi Osonuga
MAMuinat Moronke Adeyanju
Muinat Moronke Adeyanju
RORhoda Oluwaseun Olalekan
Rhoda Oluwaseun Olalekan
Background: Metabolic syndrome (MetS) encompasses a cluster of metabolic disorders including central obesity, elevated triglycerides, low HDL cholesterol, high blood pressure, and elevated fasting glucose. These disorders collectively heighten the risk of cardiovascular disease (CVD), insulin resistance, and type 2 diabetes mellitus (T2DM). With its increasing global prevalence, MetS presents significant public health challenges that necessitate comprehensive management strategies. Traditional treatments primarily involve pharmacological interventions, which are often associated with adverse effects and can lead to patient non-compliance. Main body: Nutraceuticals represent a promising alternative to conventional treatments for MetS. These compounds, derived from whole foods and dietary supplements, are being investigated for their potential benefits in improving insulin sensitivity, and lipid profiles, reducing inflammation, and addressing various components of MetS. This review critically evaluates clinical studies focused on nutraceuticals and their efficacy in enhancing metabolic health. By examining a range of interventions, the review provides evidence supporting the role of nutraceuticals in managing MetS. Conclusion: The findings of this review are pertinent to patients, researchers, and medical practitioners. For patients, nutraceuticals offer a potentially safer and more tolerable management option that could improve treatment adherence and quality of life. Researchers will benefit from understanding the mechanisms of action of these comp ounds, which can guide future studies aimed at optimizing their clinical use. Medical practitioners can utilize the insights provided to integrate nutraceuticals into their therapeutic strategies, promoting a more holistic approach to managing MetS and mitigating the burden of related chronic diseases. This comprehensive analysis serves as a foundation for advancing patient care and public health in the context of MetS.

30 September 2024 in Bulletin of the National Research Centre
Verified
Journal Article
Open access
PDF file
SOSamuel Oluwadare Olalekan
Samuel Oluwadare Olalekan
OBOlalekan Olanrewaju Bakare
Olalekan Olanrewaju Bakare
AFAbayomi Samson Faponle
Abayomi Samson Faponle
POPatrick Godwin Okwute
Patrick Godwin Okwute
Background: Hypertension is a prevalent and complex disease that is increasingly recognized to be influenced by the gut microbiome and its metabolites. Understanding the relationship between gut microbial metabolites and blood pressure regulation could provide new therapeutic avenues. Main body: This review examines the role of key microbial metabolites—short-chain fatty acids, trimethylamine N-oxide, tryptophan derivatives, polyamines, bile acids, and phenylacetylglutamine—in blood pressure regulation. Short-chain fatty acids, produced through dietary fiber fermentation, can lower blood pressure by modulating immune responses and reducing inflammation. Elevated trimethylamine N-oxide levels are associated with increased cardiovascular risk and hypertension, influencing cholesterol metabolism and promoting atherosclerosis. Tryptophan derivatives interact with vascular and renal functions to modulate blood pressure. Polyamines affect blood pressure regulation through their impact on nitric oxide synthesis and vascular tone. Bile acids influence blood pressure via gut microbiota modulation and activation of metabolic receptors. Phenylacetylglutamine has been linked to hypertension through its effects on platelet hyperactivity and thrombosis. Therapeutic approaches targeting these metabolites, including probiotics, prebiotics, fecal microbiota transplantation, dietary interventions, and polyphenols, have shown varying degrees of success. Probiotics and prebiotics promote the growth of beneficial gut bacteria and may lower blood pressure. Dietary interventions, such as the Mediterranean diet, positively affect blood pressure and cardiovascular health by modulating the gut microbiota. Polyphenols, known for their antioxidant properties, are associated with blood pressure reductions and improved vascular function. Fecal microbiota transplantation shows promise in restoring gut microbial balance and improving metabolic health, potentially influencing blood pressure regulation. Conclusion: The review highlights the significant role of gut microbial metabolites in regulating blood pressure, offering new avenues for hypertension management. Key metabolites, including short-chain fatty acids, trimethylamine N-oxide, and bile acids, play critical roles in blood pressure modulation. Therapeutic strategies targeting these metabolites, such as probiotics, prebiotics, and dietary interventions, hold promise, though further research is needed to fully understand their mechanisms and optimize their use. Advancing microbiota-based interventions through large-scale studies and exploring personalized therapies will be essential for developing effective treatments in hypertension management.

22 August 2024 in Journal of Molecular Structure
Verified
Journal Article
Open access
SOSegun D. Oladipo
Segun D. Oladipo
RLRobert Luckay
Robert Luckay
ABAbosede A. Badeji
Abosede A. Badeji
SZSizwe Zamisa
Sizwe Zamisa
SOSamuel Oluwadare Olalekan
Samuel Oluwadare Olalekan
POPeter Olusakin Oladoye
Peter Olusakin Oladoye

18 October 2024 in Clinical Phytoscience
Verified
Journal Article
Open access
PDF file
SOSamuel Oluwadare Olalekan
Samuel Oluwadare Olalekan
POPatrick Godwin Okwute
Patrick Godwin Okwute
IOIfabunmi Oduyemi Osonuga
Ifabunmi Oduyemi Osonuga
MAMuinat Moronke Adeyanju
Muinat Moronke Adeyanju
Neuropathy is a complex condition characterized by nerve damage and a wide range of symptoms, creating significant challenges in clinical management. Traditional pharmacological treatments often present partial efficacy and adverse side effects, prompting increasing interest in botanical interventions. This review evaluates the effectiveness of various plants in treating neuropathy and neuropathic pain, focusing on their pharmacological properties, mechanisms of action, clinical studies, dosage, and safety profiles. Notable plants include Crocus sativus (saffron), Citrullus colocynthis (bitter apple), Curcuma longa (turmeric), Lavandula angustifolia (lavender), and Cannabis sativa. These botanicals demonstrate anti-inflammatory, antioxidative, and analgesic effects, highlighting their potential to reduce neuropathic pain and improve patients’ quality of life. Future research should focus on optimizing dosages, clarifying long-term effects, and integrating botanicals into broader treatment protocols for neuropathic care.

7 January 2025 in The Egyptian Heart Journal
Verified
Journal Article
Open access
PDF file
SOSamuel Oluwadare Olalekan
Samuel Oluwadare Olalekan
OBOlalekan Olanrewaju Bakare
Olalekan Olanrewaju Bakare
POPatrick Godwin Okwute
Patrick Godwin Okwute
IOIfabunmi Oduyemi Osonuga
Ifabunmi Oduyemi Osonuga
MAMuinat Moronke Adeyanju
Muinat Moronke Adeyanju
VEVictoria Biola Edema
Victoria Biola Edema
Background: Hypertrophic cardiomyopathy (HCM) is a frequently encountered cardiac condition worldwide, often inherited, and characterized by intricate phenotypic and genetic manifestations. The natural progression of HCM is diverse, largely due to mutations in the contractile and relaxation proteins of the heart. These mutations disrupt the normal structure and functioning of the heart muscle, particularly affecting genes that encode proteins involved in the contraction and relaxation of cardiac muscle. Main body: This review focused on understanding the role of contractile and relaxation proteins in the pathogenesis of hypertrophic cardiomyopathy. Mutations in contractile proteins such as myosin, actin, tropomyosin, and troponin are associated with hypercontractility and increased sensitivity of the heart muscle, leading to HCM. Additionally, impaired relaxation of the heart muscle, linked to abnormalities in proteins like phospholamban, sarcolipin, titin, myosin binding protein-C, and calsequestrin, contributes significantly to the disease. The review also explored the impact of targeted therapeutic approaches aimed at modulating these proteins to improve patient outcomes. Recent advances in therapeutic strategies, including novel pharmacological agents like mavacamten and aficamten, were examined for their potential to help patients manage the disease and lead more accommodating lifestyles. Conclusions: The review underscored the significance of early diagnosis and personalized treatment approaches in managing HCM. Future research should prioritize the development of robust biomarkers for early detection and risk stratification, particularly in diverse populations, to enhance clinical outcomes. Furthermore, it is imperative to delve deeper into the genetic mutations and molecular mechanisms associated with HCM, with a focus on exploring the roles of less-studied myocardial relaxation proteins and their interactions with sarcomere constituents.